Observational study of dronedarone in Taiwanese patients with atrial fibrillation

doi:10.1016/j.jfma.2019.03.009

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24936

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24936

题名:	Observational study of dronedarone in Taiwanese patients with atrial fibrillation
作者:	Lin, JL;Wu, TJ;Chen, CP;Hsu, JC;Ueng, KC;Kuo, JY;Chen, MC;Yeh, KH;Chang, KC;Lu, YY;Shyu, KG;Wen, MS;Chen, SA;Hsieh, MH;Tseng, WK;Feng, AN;Yang, TY;Ko, WC;Cheng, CW;Liu, JC;Lai, WT
关键词:	Atrial fibrillation;Dronedarone;Observational;Safety;Quality of life
日期:	2020
上传时间:	2022-08-09T08:10:28Z (UTC)
出版者:	ELSEVIER TAIWAN
ISSN:	0929-6646
摘要:	Background/Purpose: Currently, data on the real-world use of dronedarone, an antiarrhythmic drug for atrial fibrillation (AF), are contradictory and often based on patient populations comprised of Caucasians. We prospectively investigated the efficacy and safety of dronedarone and risk factors related to treatment outcomes in a real-world use setting. Methods: The prospective, observational, single-arm, multi-center study included a total of 824 Taiwanese patients with a diagnosis of paroxysmal or persistent AF and receiving dronedarone treatment. Risk factors analysis, efficacy, and safety of dronedarone were assessed with a follow-up of six months. Results: Of the 824 patients enrolled (mean age, 75.3 +/- 7.2 years), 95.2% had at least one cardiovascular risk factor. An increase in the proportion of patients with sinus rhythm following treatment was seen (52.1% at baseline vs. 67.4% at 6 months). A decrease in the mean duration of AF episodes (388.4 min vs. 62.3 min) and an increase in total AFEQT (65.4 +/- 16.2 vs. 74.0 +/- 11.8) were also observed after 6 months of treatment. Females, those under the age of 75, and those with symptomatic AF had higher odds of treatment success. At 6 months, 10.5% of patients reported treatment-related AEs. However, only 0.2% of the AEs were both severe in nature and causally related to dronedarone. Conclusion: This six-month study showed dronedarone to be relatively safe and efficacious and to improve quality-of-life in Taiwanese patients with atrial fibrillation. Odds of treatment success were related to the patient's gender, age, and AF type. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC.
URI:	http://dx.doi.org/10.1016/j.jfma.2019.03.009 https://www.webofscience.com/wos/woscc/full-record/WOS:000504747900009 https://ir.csmu.edu.tw:8080/handle/310902500/24936
關聯:	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION ,2020 ,v119 ,issue 1 ,p59-68
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	217	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....